{"nctId":"NCT00122317","briefTitle":"Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)","startDateStruct":{"date":"2005-05","type":"ACTUAL"},"conditions":["Paroxysmal Hemoglobinuria, Nocturnal"],"count":187,"armGroups":[{"label":"Eculizumab","type":"EXPERIMENTAL","interventionNames":["Drug: eculizumab"]}],"interventions":[{"name":"eculizumab","otherNames":["Soliris"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have fully completed the TRIUMPH, SHEPHERD, or X03-001 studies\n* TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures\n* Patient must be willing and able to give written informed consent\n* Patient must avoid conception during the trial\n\nExclusion Criteria:\n\n* Patients who have terminated early from the SHEPHERD or X03-001 studies\n* Patients who have terminated early from the TRIUMPH study due to an adverse event\n* Female who is pregnant, breast feeding, or intending to conceive during the course of the study\n* Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment-emergent Adverse Events","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null}]}]}]},{"type":"SECONDARY","title":"Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-365185.8","spread":"210407.1"}]}]}]},{"type":"SECONDARY","title":"Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline","description":"The FACIT-Fatigue scale is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.24","spread":"12.42"}]}]}]},{"type":"SECONDARY","title":"Incidence of Thrombosis After Eculizumab Infusion","description":"Thrombosis was defined as occurrence of major adverse vascular events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":57,"n":187},"commonTop":["Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Diarrhoea","Nausea"]}}}